Dedicated to developing and commercializing treatments for cardiometabolic and inflammatory diseases.

Changing the Paradigm for High-Quality Weight Loss and Atherosclerotic Coronary Artery Disease

Veru is focused on the development of enobosarm, a novel, oral, selective androgen receptor modulator (SARM) to address one of the most significant adverse effects, the loss of muscle, in patients undergoing weight loss therapy with glucagon-like peptide-1 (GLP-1) drugs.

The Company is also focused on the development of sabizabulin, a novel, oral broad anti-inflammatory agent to treat atherosclerotic coronary artery disease.

“We want to be there for patients undergoing GLP-1 therapy for weight loss to avoid the side effect of muscle loss while also furthering high-quality weight loss. Our goal is to make the weight loss process as healthy as it can be, ultimately benefiting patients and making their lives better. We are extremely excited to advance enobosarm to address this major health problem.”

— Dr. Mitchell Steiner, Veru’s Chief Executive Officer